Directorate Change
No summary for this filing – the full text is below.
Select text to share a quote on X · sign in to keep highlights & notes in your SVNS notes
Graft Polymer (UK) Plc (LON: GPL), an innovative biopolymer drug delivery systems development company, announces the resignation of Mr. Pavel Kobzev from its board of directors with immediate effect. This follows the Company's recent divestiture of its industrial plastics business unit, Graft Polymer D.O.O., announced on 3 May 2024, and the successful completion of its recent fundraise, details of which were announced on 3 July 2024.
Additionally, the Company is pleased to announce the launch of its new corporate website and updated LinkedIn and X (formerly Twitter) profiles. These platforms are designed to reflect the Company's strategic focus on supporting biopharmaceutical companies to enhance the bioavailability, pharmacokinetics, and stability of their therapeutics.
Visit us online:
X (formerly Twitter)
Graft Polymer (UK) Plc (LON:GPL) is an innovative developer of biopolymer drug delivery systems dedicated to assisting biopharmaceutical companies in enhancing the effectiveness of their therapeutics. Our proprietary patented platform, a bioabsorbable self-nanoemulsifying drug delivery system (SNEDDS), represents a cutting-edge solution in drug delivery technology. By integrating active pharmaceutical ingredients (APIs) into our novel, patented delivery systems, we enable clients to improve the bioavailability, pharmacokinetics, and stability of their therapeutics.
| www.graftpolymer.co.uk | X (formerly Twitter) |
Cleaned text: letterheads, contacts and legal notices removed. View the original announcement ↗ · Company filings. Not investment advice.